




RealRate

# PHARMACEUTICAL 2022

Nascent Biotech Inc.  
Rank 405 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • [www.realrate.ai](http://www.realrate.ai)



# PHARMACEUTICAL 2022

Nascent Biotech Inc.  
Rank 405 of 475

The relative strengths and weaknesses of Nascent Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nascent Biotech Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 245% points. The greatest weakness of Nascent Biotech Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 518% points.

The company's Economic Capital Ratio, given in the ranking table, is -447%, being 170% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	751
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,224
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,469
Other Liabilities	0
Other Net Income	442
Property and Equipment	0
Research and Development	322
Revenues	750
Selling, General and Administrative Expense	359

Output Variable	Value in 1000 USD
Assets	751
Liabilities	1,224
Expenses	2,150
Stockholders Equity	-473
Net Income	-959
Comprehensive Net Income	-959
Economic Capital Ratio	-447%

